|
FR2740339B1
(fr)
*
|
1995-10-26 |
1997-12-05 |
Oreal |
Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
|
|
US6369272B1
(en)
|
1997-01-13 |
2002-04-09 |
Glaxosmithkline |
Nitric oxide synthase inhibitors
|
|
US6620848B2
(en)
|
1997-01-13 |
2003-09-16 |
Smithkline Beecham Corporation |
Nitric oxide synthase inhibitors
|
|
MY117948A
(en)
|
1997-01-13 |
2004-08-30 |
Glaxo Group Ltd |
Nitride oxide synthase inhibitors.
|
|
WO1998033379A1
(en)
*
|
1997-02-04 |
1998-08-06 |
The General Hospital Corporation |
A novel method for treating epidermal or dermal conditions
|
|
AU8647198A
(en)
*
|
1997-08-12 |
1999-03-01 |
Chugai Seiyaku Kabushiki Kaisha |
Remedies for diseases associated with bone resorption
|
|
ES2239839T3
(es)
*
|
1998-03-11 |
2005-10-01 |
G.D. Searle Llc |
Derivados de amidino-amino-acidos halogenados utiles como inhibidores de la oxido nitrico-sintasa.
|
|
US6284735B1
(en)
*
|
1998-04-28 |
2001-09-04 |
Lion Bioscience Ag |
HP-3228 and related peptides to treat sexual dysfunction
|
|
US6534503B1
(en)
|
1998-04-28 |
2003-03-18 |
Lion Bioscience Ag |
Melanocortin receptor-3 ligands to treat sexual dysfunction
|
|
WO1999055679A1
(en)
|
1998-04-28 |
1999-11-04 |
Trega Biosciences, Inc. |
Isoquinoline compound melanocortin receptor ligands and methods of using same
|
|
GB9811599D0
(en)
|
1998-05-30 |
1998-07-29 |
Glaxo Group Ltd |
Nitric oxide synthase inhibitors
|
|
WO2001005401A1
(en)
*
|
1999-07-16 |
2001-01-25 |
Trega Biosciences, Inc. |
Melanocortin receptor-3 ligands to treat sexual dysfunction
|
|
ATE295832T1
(de)
*
|
2000-03-24 |
2005-06-15 |
Pharmacia Corp |
Amidino-verbindung sowie salze davon verwendbar als hemmstoffe der stickstoffmonoxid-synthase
|
|
AR034120A1
(es)
*
|
2000-04-13 |
2004-02-04 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
|
|
GB0031179D0
(en)
*
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Nitric oxide synthase inhibitors
|
|
DE10111052A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Steigerung der Ceramidbiosynthese
|
|
DE10111054A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
|
|
DE10111050A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
|
|
DE10111049A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
|
|
US7012098B2
(en)
*
|
2001-03-23 |
2006-03-14 |
Pharmacia Corporation |
Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
|
|
MXPA04011335A
(es)
*
|
2002-05-16 |
2005-07-01 |
Pharmacia Corp |
Metodos para el tratamiento de enfermedades y afecciones respiratorias con un inhibidor selectivo de inos y un inhibidor de pde y composiciones para esto.
|
|
GB0214147D0
(en)
*
|
2002-06-19 |
2002-07-31 |
Glaxo Group Ltd |
Formulations
|
|
WO2004080956A1
(en)
*
|
2003-03-11 |
2004-09-23 |
Pharmacia Corporation |
S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt
|
|
TWI328009B
(en)
|
2003-05-21 |
2010-08-01 |
Glaxo Group Ltd |
Quinoline derivatives as phosphodiesterase inhibitors
|
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
|
CN1894251B
(zh)
*
|
2003-11-17 |
2011-06-29 |
默克和西伊公司 |
(6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型
|
|
PE20060272A1
(es)
|
2004-05-24 |
2006-05-22 |
Glaxo Group Ltd |
(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
|
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
|
GB0418045D0
(en)
|
2004-08-12 |
2004-09-15 |
Glaxo Group Ltd |
Compounds
|
|
EP1841780B1
(en)
|
2005-01-10 |
2011-07-27 |
Glaxo Group Limited |
Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
|
|
TW200724142A
(en)
|
2005-03-25 |
2007-07-01 |
Glaxo Group Ltd |
Novel compounds
|
|
PE20061351A1
(es)
|
2005-03-25 |
2007-01-14 |
Glaxo Group Ltd |
COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
|
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
|
DE102005047946A1
(de)
*
|
2005-10-06 |
2007-05-03 |
Bayer Healthcare Ag |
Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
|
|
PE20071068A1
(es)
|
2005-12-20 |
2007-12-13 |
Glaxo Group Ltd |
Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
|
|
KR20090003349A
(ko)
|
2006-04-20 |
2009-01-09 |
글락소 그룹 리미티드 |
화합물
|
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
|
PT2046787E
(pt)
|
2006-08-01 |
2011-06-15 |
Glaxo Group Ltd |
Compostos de pirazolo[3,4-b]piridina e sua utilização como inibidores de pde4
|
|
US20080114021A1
(en)
*
|
2006-11-09 |
2008-05-15 |
University Of Maryland Baltimore |
Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
|
|
PE20081889A1
(es)
|
2007-03-23 |
2009-03-05 |
Smithkline Beecham Corp |
Indol carboxamidas como inhibidores de ikk2
|
|
CN102137858B
(zh)
|
2008-05-23 |
2014-07-23 |
潘米拉制药有限责任公司 |
5-脂氧合酶-活化蛋白抑制剂
|
|
JP5502858B2
(ja)
|
2008-06-05 |
2014-05-28 |
グラクソ グループ リミテッド |
Pi3キナーゼの阻害剤として有用な4−カルボキサミドインダゾール誘導体
|
|
JP5502077B2
(ja)
|
2008-06-05 |
2014-05-28 |
グラクソ グループ リミテッド |
新規な化合物
|
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
|
EP2406255B1
(en)
|
2009-03-09 |
2015-04-29 |
Glaxo Group Limited |
4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
|
|
WO2010102968A1
(en)
|
2009-03-10 |
2010-09-16 |
Glaxo Group Limited |
Indole derivatives as ikk2 inhibitors
|
|
WO2010106016A1
(en)
|
2009-03-17 |
2010-09-23 |
Glaxo Group Limited |
Pyrimidine derivatives used as itk inhibitors
|
|
WO2010107958A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
JP2012520683A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた結合組織増殖因子(CTGF)遺伝子発現のRNA干渉媒介性阻害
|
|
CA2755773A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
|
|
WO2010107957A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
|
MX2011010072A
(es)
|
2009-03-27 |
2011-10-06 |
Merck Sharp & Dohme |
Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia.
|
|
US20120010272A1
(en)
|
2009-03-27 |
2012-01-12 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
EP2411520A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
WO2010111471A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP2421834A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
|
JP2012524755A
(ja)
|
2009-04-24 |
2012-10-18 |
グラクソ グループ リミテッド |
Cracチャネル阻害剤としてのn−ピラゾリルカルボキサミド
|
|
AR076435A1
(es)
|
2009-04-30 |
2011-06-08 |
Glaxo Group Ltd |
Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
|
|
EP2486004B1
(en)
*
|
2009-10-09 |
2017-05-03 |
Zafgen, Inc. |
Sulphone compounds for use in the treatment of obesity
|
|
WO2011067365A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of p13 kinases
|
|
JP2013512878A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
新規化合物
|
|
JP2013512880A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
Pi3−キナーゼ阻害剤としてのインダゾール誘導体
|
|
EP2512438B1
(en)
|
2009-12-16 |
2017-01-25 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
|
JP5876051B2
(ja)
|
2010-09-08 |
2016-03-02 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
|
|
RS54286B1
(sr)
|
2010-09-08 |
2016-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
|
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
|
WO2012052459A1
(en)
|
2010-10-21 |
2012-04-26 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
|
EP2630126B1
(en)
|
2010-10-21 |
2015-01-07 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, immune and inflammatory conditions
|
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
|
EP2683716A1
(en)
|
2011-03-11 |
2014-01-15 |
Glaxo Group Limited |
Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
|
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
|
EP3046921A4
(en)
|
2013-09-22 |
2017-02-22 |
Calitor Sciences, LLC |
Substituted aminopyrimidine compounds and methods of use
|
|
JP6517319B2
(ja)
|
2014-03-28 |
2019-05-22 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc |
置換されたヘテロアリール化合物および使用方法
|
|
WO2015173701A2
(en)
|
2014-05-12 |
2015-11-19 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pharmaceutical compositions for treating infectious diseases
|
|
GB201512635D0
(en)
|
2015-07-17 |
2015-08-26 |
Ucl Business Plc |
Uses of therapeutic compounds
|
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
BR112022019245A2
(pt)
|
2020-03-26 |
2022-11-16 |
Glaxosmithkline Ip Dev Ltd |
Inibidores de catepsina para prevenir ou tratar infecções virais
|